Gastroparesis Market Overview

The global Gastroparesis market is estimated to be worth over USD 11,895.83 Mn in 2033 and is expected to grow at CAGR of 3.6% during the forecast period (2024-2033). Gastroparesis can be perceived as a gastrointestinal disorder marked by deferred emptying of the stomach contents into the small intestine, resulting in symptoms such as vomiting, nausea, bloating, abdominal pain, and early satiety. This condition results from malfunction of the muscles or nerves commanding stomach movement, oftentimesrelated to conditions such as neurological disorders, diabetes, or post-surgical complications. The global market for gastroparesis surroundsdifferent sectors, including medical devices, pharmaceuticals, and supportive therapies, focused at administering symptoms, enhancing quality of life, and addressing the underlying causes of the condition.

In recent times, treatment alternatives for gastroparesis are limited, with no curative therapies available. Nonetheless, pharmaceutical interventions such as antiemetics, prokinetic agents, and symptom management medications are generally prescribed to lessen symptoms and support gastric motility. In addition to that, medical devices such as gastric electrical stimulators are likely to be used in refractory cases to modulate stomach contractions and enhance gastric emptying. Supportive therapies such as nutritional supplementation, dietary modifications, and behavioral therapies are also crucialelements of gastroparesis management. Notwithstanding the existing challenges, the global market for gastroparesis is witnessinginnovations in research and innovation, with continuing efforts focused on developing novel treatments and diagnostic tools. Emerging therapies targeting novel mechanisms of action, such as ghrelin receptor agonists, gastric pacemakers, and neuromodulation techniques, provide promise for enhancing outcomes and addressing unmet needs in gastroparesis management.

Along with that, the consolidation of digital health technologies, comprising mobile applications for symptom tracking and telemedicine platforms for remote patient monitoring, is transforming patient care and improving treatment adherence. With the prevalence of gastroparesis on the rise, led by factors such as growing incidence of diabetes and obesity, the global market for gastroparesis is poised for robust growth, presenting opportunities for investment, innovation, and collaboration aimed at enhancing outcomes for patients affected by this chronic and debilitating condition.

Figure 1. Gastroparesis: Market Size

Get more details on this report - Request Free Sample

Key Market Insights &Current Market Landscape:

Gastroparesis, formerlyconsidered as a rare ailment, is complicated to diagnose and arduous to treat, there were several breakthrough advances in the 2010s, changing the paradigm of the understanding of this challenging entity and its management. Equivalent to diabetes, its growing prevalence indicates increased accessibility to diagnostic modalities and implies that gastroparesis was underassessed in the past. Significant developments in the three major facets of the disease comprise the discovery of smooth muscle cells, PDGFRα+ cells syncytium, interstitial cells of Cajal, in place of interstitial cells of Cajal alone, as the primary gastric pacemaker unit; the development of validated point-of-care diagnostic modalities such as a wireless motility capsule, the carbon 13-labeled breath test, and impedance planimetry; and the foreword of novel minimally invasive therapeutic alternatives such as novel pharmacologic agents and gastric peroral endoscopic pyloromyotomy. 

Emerging therapies targeting novel mechanisms of action, comprising gastric neuromodulation and ghrelin receptor agonists, providecommitment for enhancing symptoms and gastric motility. In addition to that, innovatios in diagnostic technologies, such as wireless motility capsules and gastric emptying scintigraphy, allow more accurate diagnosis and monitoring of gastroparesis.

Market Dynamics

Market Drivers

Rise in the Prevalence of Idiopathic Gastroparesis

Idiopathic gastroparesis, defined by deferred gastric emptying without an identifiable cause, accounts for a substantial portion of gastroparesis cases. With the incidence of gastroparesis on the surge, fueled by factors such as soaring rates of obesityand diabetes, the proportion of idiopathic cases is also rising. This trend intensifies the demand for effective treatments and management strategies to tackle the symptoms and underlying pathophysiology of gastroparesis. Healthcare providers are experienced with the dispute of managing an upsurge in the number of patients with idiopathic gastroparesis, requiring advancements in diagnostic tools, therapeutic alternatives, and supportive care approaches. Asa consequence, pharmaceutical firms, medical device manufacturers, and healthcare companies are investing in research and innovation to develop newer treatments and enhance outcomes for patients with idiopathic gastroparesis. By addressing the particular needs of this patient population, the global gastroparesis market stands ready for growth, representing opportunities for collaboration,investment, and advancement in the domain of gastrointestinal disorders.

Market Restraints

With regard to numerous advantages of Gastroparesis, the market faces several challenges due to the unique characteristics and requirements associated with them. Some of the key market challenges include:

• Limited Treatment Options: The global gastroparesis market witnesses a hindranceowing to the limited availability of effective treatment alternatives, with existing therapies oftentimesoffering only symptomatic relief and not addressing the underlying cause of the condition.
• Diagnostic Challenges: Diagnostic challenges, comprising the lack of standardized diagnostic criteria and the intricacy of differentiating gastroparesis from other gastrointestinal disorders, impede accurate and timely diagnosis, potentially delaying appropriate management and treatment initiation.

Market Opportunities

Increase in the Surgeries can Cause Post-Operative Gastroparesis

The rise in surgeries presents a notable market opportunity for the global gastroparesis market, specifically concerning post-operative gastroparesis. Surgical procedures, particularly those including the abdomen or gastrointestinal tract, can interrupt normal gastric motility and contribute to the development of gastroparesis in some patients. As surgical interventions become more prevalent for different medical conditions, the prevalence of post-operative gastroparesis is estimated to surge, fueling demand for effective management and treatment strategies. Healthcare providers are increasingly identifying the prominence of recognizing and addressing post-operative gastroparesis to avoidcomplexities and enhance patient outcomes. As a consequence, there is soaring interest in the development of therapeutic interventions and supportive care approaches customized to the specialized needs of patients with post-operative gastroparesis. Pharmaceutical firms, medical device manufacturers, and healthcare organizations are investing in research and innovation to develop diagnostic tools, targeted therapies, and post-operative management protocols for this patient population. By addressing the specific challenges posed by post-operative gastroparesis, the global gastroparesis market can diversify its scope and reach, providing solutions to enhance the quality of life for individuals affected by this condition following surgical procedures.

Market Trends

• Rising Demand for Minimally Invasive Therapies: There is a trend towards the adoption of minimally invasive therapeutic approaches, such as gastric neuromodulation and endoscopic treatments, for the administration of gastroparesis. These techniques provide potential advantages in terms of mitigated procedural invasiveness, lesser recovery times, and enhanced patient outcomes.
• Integration of Digital Health Solutions: Digital health solutions, comprising mobile applications for symptom tracking, telemedicine platforms for remote patient monitoring, and wearable devices for physiological monitoring, are increasingly being consolidated into gastroparesis management. These technologies improve patient engagement, support data-driven decision-making, and enhance communication between patients and healthcare providers, ultimately paving its way to more personalized and effective care delivery.

Get more details on this report - Request Free Sample

Gastroparesis Market: Key Segments

By Type

• Idiopathic
• Diabetic
• Post- Surgical
• Others

By Drug Class

• Prokinetic Drugs
• Antiemetics
• Botulinum Toxin Injection
• Antidepressants
• Others

By Treatment

• Jejunostomy
• Gastric Electric Stimulation
• Parenteral Nutrition
• Diabetic Gastroparesis
• Chronic Gastroparesis
• Idiopathic Gastroparesis
• Post-Operative Gastroparesis

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Others

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America 

Gastroparesis Market: Regional Analysis

North America dominates the gastroparesis market attributing to the rise in the number of diabetic patients. Furthermore, the diabetic gastroparesis is considered one of the major procedures of gastroparesis that is affecting the population will further boost the growth of the gastroparesis market in the region during the forecast period. Asia-Pacific is projected to observe the growth in the gastroparesis market due to the rise in the standard pace of diabetes. Moreover, the vast untapped market potential amongst the advancing countries is further anticipated to propel the growth of the gastroparesis market in the region in the coming years.

Figure 4. Gastroparesis Market: Distribution by Region

Get more details on this report - Request Free Sample

Leading Gastroparesis Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the Gastroparesismarket, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the Gastroparesismarket are briefly discussed below. 

The report includes the list of players operating in the global Gastroparesismarket. Some of the key players include: 

• Abbott
• Amneal Pharmaceuticals LLC
• ALLERGAN
• Annora Pharma Pvt
• AbbVie Inc
• CAIRN DIAGNOSTICS
• Bristol-Myers Squibb Company
• bioMérieux, Inc
• Bio-Rad Laboratories, Inc
• Bayer AG
• CAIRN DIAGNOSTICS
• Evoke Pharma
• Lupin Pharmaceuticals Inc.
• Endologic
• Medtronic
• Novartis AG
• Neurogastrx, Inc.
• Pfizer Inc
• Takeda Pharmaceutical Company Limited.
• Theravance Biopharma
• Thermo Fisher Scientific

Recent Developments in the Gastroparesis Market

Several recent developments have taken place in the field of Gastroparesis, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis chronologically.

• In December 2023, Vanda Pharmaceuticals Inc. VNDA announced that the FDA accepted its NDA filing seeking approval for its NK-1R antagonist, tradipitant, for the treatment of symptoms of gastroparesis.The FDA gave the application a standard review and a decision from the regulatory body is expected on Sep 18, 2024.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: